These data suggest that bryostatin-1 may potentially enhance CD8+ T cell responses by targeting exhausted CD8+ T cells in the treatment of infections insufficiently controlled by available therapies, to help in eradicating HIV reservoir cells, or by improving the effectiveness of cancer immunotherapy. Here, CD8A is linked to cancer.